IDSA, AAN, and ACR Release Guidelines for Prevention, Diagnosis, and Treatment of Lyme Disease
Newswise — New evidence-based clinical practice guidelines for the prevention, diagnosis, and treatment of Lyme disease have been developed by a multidisciplinary panel led by the Infectious Diseases Society of America, the American Academy of Neurology, and the American College of Rheumatology. Representatives from an additional 12 medical specialties and patients also served on the panel.
The guidelines provide practical recommendations for clinicians treating patients with Lyme disease, including, but not limited to, primary care physicians, infectious diseases specialists, emergency physicians, internists, pediatricians, family physicians, neurologists, rheumatologists, cardiologists, and dermatologists.
These recommendations aim to serve as a meaningful resource for the safe, effective, evidence-based care of people with Lyme disease. They address clinical questions related to the prevention, diagnosis, and treatment of Lyme disease; complications from neurologic, cardiac, and rheumatic symptoms; disease expression commonly seen in Eurasia; and complications from coinfection with other tick-borne pathogens.
The guidelines include 43 recommendations related to diagnostic testing, including testing scenarios (such as for certain neurologic, psychologic, behavioral, cardiac, and rheumatologic syndromes); detailed recommendations about Lyme carditis; and a discussion of “chronic Lyme disease.”
Among the diagnostic testing recommendations, the guidelines recommend clinical diagnosis without laboratory testing for people with a skin rash characteristic of early Lyme disease. For people with other signs of Lyme disease, such as swollen joints or meningitis, the guidelines recommend antibody testing.
Among the treatment recommendations, the guidelines recommend oral antibiotic therapy for most patients with Lyme disease. The recommended duration of therapy is 10 to 14 days for early Lyme disease, 14 days for Lyme carditis, 14 to 21 days for neurologic Lyme disease, and 28 days for late Lyme arthritis. Retreatment may be indicated for individuals with arthritis who have failed a first course of treatment.
The recommendations are grounded in a rigorous, systematic review of available evidence surrounding prevention, diagnosis and treatment of the disease. The panel adhered to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess the certainty of the evidence and strength of recommendations. The guidelines are voluntary and it is up to clinicians to determine which treatments are best for individual patient scenarios.
Each of the three sponsoring organizations elected a co-chair to lead the guideline panel. A fourth co-chair was selected for their expertise in guideline methodology. A total of 36 panelists comprised the full panel, and the panel also included three patient representatives and one health care consumer representative.
About 30,000 cases of Lyme disease are reported annually, but the Centers for Disease Control and Prevention estimates there are more than 300,000 cases in the United States each year.
The Infectious Diseases Society of America is a community of over 12,000 physicians, scientists, and public health experts who specialize in infectious diseases. Its purpose is to improve the health of individuals, communities, and society by promoting excellence in patient care, education, research, public health, and prevention relating to infectious diseases. Learn more at https://www.idsociety.org/.
The American Academy of Neurology is the world’s largest association of neurologists and neuroscience professionals, with more than 36,000 members. The AAN is dedicated to promoting the highest quality patient-centered neurologic care. Learn more at https://www.aan.com/.
The American College of Rheumatology (ACR) is an international medical society representing over 7,700 rheumatologists and rheumatology health professionals with a mission to empower rheumatology professionals to excel in their specialty. In doing so, the ACR offers education, research, advocacy, and practice management support to help its members continue their innovative work and provide quality patient care. Learn more at https://www.rheumatology.org/
For those of you new to the world of tick-borne illness, please read: https://madisonarealymesupportgroup.com/2020/09/25/why-should-we-care-about-lyme-disease-a-colorful-tale-of-government-conflicts-of-interest-probable-bioweaponization-and-pathogen-complexity/ This article will fill you in on the ugly, sordid back-story of Lyme/MSIDS. It will educate you on the polarization within the medical community and that your best help will come from Lyme literate doctors trained by ILADS. They appreciate the complexity of this illness and that it takes numerous anti-microbials for a longer period of time than what the IDSA/CDC state.
For ILADS 2014 Guidelines: https://www.tandfonline.com/doi/full/10.1586/14787210.2014.940900
ILADS Lyme 101 Series: https://www.ilads.org/research-literature/lyme-101-series-at-iladef/
ILADS Basics for Providers: https://www.ilads.org/research-literature/lyme-disease-basics-for-providers/
https://madisonarealymesupportgroup.com/category/lyme-disease-treatment/ Within this link is a link that leads you to an article in Antibiotics on : “Chronic Lyme Disease: An Evidence-Based Definition by the ILADS Working Group“. It also includes an article utilizing numerous Lyme literate doctors’ clinical experience with treatment.